Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals TARS
$ 46.21 -2.3%

Quarterly report 2024-Q2
added 08-08-2024

report update icon

Tarsus Pharmaceuticals Balance Sheet 2011-2024 | TARS

Annual Balance Sheet Tarsus Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-195 M -51.5 M -170 M -168 M -57.8 M -2.36 M - - - - - - -

Long Term Debt

29.8 M 19.4 M 585 K - - - - - - - - - -

Long Term Debt Current

398 K 721 K 609 K 282 K - - - - - - - - -

Total Non Current Liabilities

- - - 605 K 63.5 M 3.56 M - - - - - - -

Total Current Liabilities

36.9 M 15.4 M 11.5 M 5.39 M - - - - - - - - -

Total Liabilities

68.5 M 35 M 12.2 M 5.99 M 64.3 M 3.74 M - - - - - - -

Deferred Revenue

- - 697 K - - - - - - - - - -

Retained Earnings

-245 M -109 M -46.7 M - -6.03 M -1.36 M - - - - - - -

Total Assets

265 M 228 M 179 M 172 M 58.3 M 2.39 M - - - - - - -

Cash and Cash Equivalents

225 M 71.7 M 171 M 168 M 58 M - - - - - - - -

Book Value

197 M 193 M 167 M 166 M -6 M -1.35 M - - - - - - -

Total Shareholders Equity

197 M 193 M 167 M 166 M -6 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Tarsus Pharmaceuticals

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

71.6 M 29.9 M 29.8 M 29.7 M 24.6 M 24.5 M 19.4 M 19.4 M 19.3 M 19.2 M - 755 K 405 K 456 K 549 K 549 K 549 K 549 K 100 K 100 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

125 M 74.1 M 68.5 M 54.7 M 41.2 M 37.8 M 35 M 33.8 M 31.3 M 32.3 M 12.2 M 11.3 M 11 M 10.7 M 5.99 M 5.99 M 5.99 M 5.99 M 919 K 919 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - 174 K 697 K 1.03 M 1.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-314 M -280 M -245 M -203 M -164 M -132 M -109 M -95.2 M -72.7 M -66.9 M -46.7 M -31.8 M -16.1 M -22.5 M -32.8 M -32.8 M -32.8 M -32.8 M -6.03 M -6.03 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

377 M 349 M 265 M 268 M 189 M 211 M 228 M 236 M 253 M 181 M 179 M 190 M 203 M 194 M 172 M 172 M 172 M 172 M 58.3 M 58.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

181 M 194 M 225 M 227 M 107 M 66 M 71.7 M 169 M 245 M 175 M 171 M 184 M 177 M 156 M 168 M 168 M 168 M 168 M 58 M 58 M - - 2.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

252 M 275 M 197 M 214 M 148 M 173 M 193 M 203 M 222 M 149 M 167 M 179 M 192 M 183 M 166 M 166 M 166 M 166 M 57.4 M 57.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

252 M 275 M 197 M 214 M 148 M 173 M 193 M 203 M 222 M 149 M 167 M 179 M 192 M 183 M 166 M 166 M 166 M 166 M -6 M -6 M -3.92 M -3.1 M -1.35 M - - - -44 K - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency